Cargando…
Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
We present a case of a 58-year-old Japanese man with a history of 2 previous COVID-19 infections, who received 2 doses of mRNA-1273 vaccine. We are not aware of any previous study regarding antibody tendency after 2 infections and 2 vaccinations. We evaluated his IgG titer of antispike protein and n...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925083/ https://www.ncbi.nlm.nih.gov/pubmed/35306204 http://dx.doi.org/10.1016/j.ijid.2022.03.017 |
_version_ | 1784669993096445952 |
---|---|
author | Inada, Makoto Ishikane, Masahiro Terada, Mari Matsunaga, Akihiro Maeda, Kenji Iwamoto, Noriko Ujiie, Mugen Kutsuna, Satoshi Morioka, Shinichiro Ishizaka, Yukihito Mitsuya, Hiroaki Ohmagari, Norio |
author_facet | Inada, Makoto Ishikane, Masahiro Terada, Mari Matsunaga, Akihiro Maeda, Kenji Iwamoto, Noriko Ujiie, Mugen Kutsuna, Satoshi Morioka, Shinichiro Ishizaka, Yukihito Mitsuya, Hiroaki Ohmagari, Norio |
author_sort | Inada, Makoto |
collection | PubMed |
description | We present a case of a 58-year-old Japanese man with a history of 2 previous COVID-19 infections, who received 2 doses of mRNA-1273 vaccine. We are not aware of any previous study regarding antibody tendency after 2 infections and 2 vaccinations. We evaluated his IgG titer of antispike protein and neutralizing activity from the first infection before and after 2 doses of vaccine. Both antispike IgG titer and neutralizing activity showed a tendency to decline almost 1 year after initial infection; they rapidly increased after the first vaccination, and they remained high after the second vaccination. Although this is a single case report, it seems to have generalizability because the findings are consistent with previous reports regarding single infections or 3 doses of vaccination. Our findings suggest that a single booster shot may provide sufficient protection and aid the understanding of immunologic responses of vaccination in patients with COVID-19 with history of re-infection. |
format | Online Article Text |
id | pubmed-8925083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89250832022-03-17 Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection Inada, Makoto Ishikane, Masahiro Terada, Mari Matsunaga, Akihiro Maeda, Kenji Iwamoto, Noriko Ujiie, Mugen Kutsuna, Satoshi Morioka, Shinichiro Ishizaka, Yukihito Mitsuya, Hiroaki Ohmagari, Norio Int J Infect Dis Case Report We present a case of a 58-year-old Japanese man with a history of 2 previous COVID-19 infections, who received 2 doses of mRNA-1273 vaccine. We are not aware of any previous study regarding antibody tendency after 2 infections and 2 vaccinations. We evaluated his IgG titer of antispike protein and neutralizing activity from the first infection before and after 2 doses of vaccine. Both antispike IgG titer and neutralizing activity showed a tendency to decline almost 1 year after initial infection; they rapidly increased after the first vaccination, and they remained high after the second vaccination. Although this is a single case report, it seems to have generalizability because the findings are consistent with previous reports regarding single infections or 3 doses of vaccination. Our findings suggest that a single booster shot may provide sufficient protection and aid the understanding of immunologic responses of vaccination in patients with COVID-19 with history of re-infection. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-06 2022-03-16 /pmc/articles/PMC8925083/ /pubmed/35306204 http://dx.doi.org/10.1016/j.ijid.2022.03.017 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Case Report Inada, Makoto Ishikane, Masahiro Terada, Mari Matsunaga, Akihiro Maeda, Kenji Iwamoto, Noriko Ujiie, Mugen Kutsuna, Satoshi Morioka, Shinichiro Ishizaka, Yukihito Mitsuya, Hiroaki Ohmagari, Norio Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection |
title | Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection |
title_full | Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection |
title_fullStr | Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection |
title_full_unstemmed | Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection |
title_short | Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection |
title_sort | antibody responses after two doses of sars-cov-2 mrna-1273 vaccine in an individual with history of covid-19 re-infection |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925083/ https://www.ncbi.nlm.nih.gov/pubmed/35306204 http://dx.doi.org/10.1016/j.ijid.2022.03.017 |
work_keys_str_mv | AT inadamakoto antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection AT ishikanemasahiro antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection AT teradamari antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection AT matsunagaakihiro antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection AT maedakenji antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection AT iwamotonoriko antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection AT ujiiemugen antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection AT kutsunasatoshi antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection AT moriokashinichiro antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection AT ishizakayukihito antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection AT mitsuyahiroaki antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection AT ohmagarinorio antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection |